甲状腺疾病治疗市场－全球产业规模、份额、趋势、机会、预测：按适应症、给药途径、分销管道、地区和竞争格局划分，2021-2031年

全球甲状腺疾病治疗市场预计将从 2025 年的 29.3 亿美元成长到 2031 年的 37.7 亿美元，复合年增长率为 4.29%。

该市场涵盖多种药物干预和治疗方法，例如左旋甲状腺素和放射性碘，用于恢復甲状腺机能低下症以及人口老化加剧，导致长期疾病管理需求增加。例如，美国癌症协会估计，到2025年，美国将新增约44,020例甲状腺癌病例。如此庞大的患者群体凸显了稳定可靠的治疗方案供应的迫切需求，并刺激了国际医疗保健系统对有效治疗方案的需求。

然而，由于新治疗方法核准的严格监管框架，该领域面临许多重大障碍。严格的合规要求和全面的安全检验往往会延缓新药的研发进程并增加营运成本。这些监管障碍有效地减缓了创新治疗方法进入商业市场的速度，并可能阻碍其在医疗基础设施尚未完善的新兴经济体中的推广。

市场驱动因素

全球甲状腺疾病盛行率的不断上升是市场成长的主要驱动力，也因此对荷尔蒙补充疗法的稳定供应产生了迫切需求。随着人口老化和诊断能力的提高，甲状腺机能低下症减退症的发生率不断上升，人们对左旋甲状腺素等标准疗法的依赖性也日益增强。这种持续的患者需求为成熟的製药公司带来了显着的商业性规模，确保了其在慢性病治疗领域的稳定收入。例如，根据默克集团2025年11月发布的报告，其旗舰甲状腺药物Eucilox在全球强劲需求的支撑下，实现了9.6%的有机净销售额增长。此外，美国食品药物管理局（FDA）2025年8月发布的新闻稿指出，2024年美国约有2,200万名患者服用左旋甲状腺素，这进一步凸显了该疾病的沉重负担。

同时，新药製剂的推出正在拓展传统非专利荷尔蒙补充疗法以外的收入来源。製药公司正大力投资生物製药和标靶治疗，以应对甲状腺眼疾（TED）和难治性甲状腺癌等复杂疾病。这些创新治疗方法为传统疗法提供了高价值的替代方案，并透过卓越的临床疗效和溢价不断扩大市场份额。安进公司在2025年第三季财报中揭露，其用于治疗甲状腺眼疾的标靶治疗Tepeza的全球销售额年增15%，达5.6亿美元。这种成长标誌着产业正朝着针对甲状腺疾病领域特定未满足需求的专科疗法方向发生重大转变。

市场挑战

严格的法规结构对全球甲状腺疾病治疗市场的成长构成重大阻碍。研发公司必须遵守复杂的合规程序，并进行全面的临床试验以验证新治疗方法的安全性和有效性。这些严格的要求显着增加了营运成本，延长了研发週期，造成了瓶颈，延缓了创新药物的商业化。因此，市场无法快速回应医疗服务提供者和患者不断变化的需求，导致商机的流失和产业发展速度的放缓。

こうした规制上の遅延による影响は、迅速かつ効果的な治疗を必要とする重大な疾病负担によってさらに深刻化しています。米国甲状腺协会（ATA）の推计によれば、2025年には约2,000万人のアメリカ人が何らかの甲状腺疾患に苦しむ见込みです。この膨大な患者数は、先进治疗方法の紧急性に対する需要と、产品核可の遅々たる进捗との乖离を浮き雕りにしています。新规治疗方法の迅速な市场参入を阻む规制上の障壁は、この広范な患者层のニーズに対応する业界の能力を制限し、ひいては市场全体の拡大を妨げています。

市场趋势

AI駆动型诊断・モニタリングソリューションの统合は、画像诊断の精度とワークフロー効率を向上させることで、甲状腺结节の临床管理に革命をもたらしています。メーカー各社は、放射线科医が甲状腺病変の一贯した検出、セグメンテーション、分类を支援するため、超音波システムへの深层学习アルゴリズムの积极的な组み込みを进めています。この技术的进化は、手动検査にありがちな主観性を軽减し、リスク评価通讯协定を标准化することで、良性结节に対する不必要な切片检查率の低减が期待されます。例えば、サムスンメディソンが2025年11月に発表した新型超音波诊断设备「R20」のプレスリリースでは、测定の自动化や复雑な症例に対するリアルタイム诊断ガイダンスを提供する10以上のAIツールを搭载している点が强调されています。

同时，针对蛋白酪氨酸激酶抑制剂在甲状腺癌治疗中的广泛应用，正在重新定义放射性碘抗药性患者的治疗选择。随着我们对甲状腺恶性肿瘤分子机制的认识不断加深，精准肿瘤疗法（例如抑制VEGFR和RET等特定路径）的应用显着增加。这种向分子标靶疗法的转变，正大幅提升製药公司的收入，因为口服药物正逐渐成为传统化疗的标准替代方案。 2025年5月，Exelisys公司公布其旗舰蛋白酪氨酸激酶抑制剂Cabometyx第一季净销售额达5.133亿美元，主要得益于包括分化型甲状腺癌在内的所有肿瘤适应症需求的成长。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球甲状腺疾病治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 适应症（甲状腺机能低下症、甲状腺功能亢进）
  • 给药途径（口服、静脉注射、其他）
  • 分销通路细分（批发商/经销商、零售连锁店、线上分销、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美甲状腺疾病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲甲状腺疾病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区甲状腺疾病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲甲状腺疾病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲甲状腺疾病治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球甲状腺疾病治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abbvie Inc.
• Amgen Inc.
• GSK Plc
• Merck KGaA
• Viatris Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Elexis Inc.
• IBSA Group

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Thyroid Gland Disorder Treatment Market is projected to expand from USD 2.93 Billion in 2025 to USD 3.77 Billion by 2031, registering a CAGR of 4.29%. This market includes various pharmaceutical interventions and therapies, including levothyroxine and radioactive iodine, designed to restore hormonal equilibrium in individuals suffering from hypothyroidism, hyperthyroidism, or thyroid cancer. Growth is largely propelled by the rising global incidence of thyroid dysfunction and an aging demographic requiring long-term disease management. For instance, the American Cancer Society estimates that roughly 44,020 new thyroid cancer cases will arise in the United States in 2025. This significant patient load highlights the urgent necessity for a reliable supply of therapeutics and stimulates demand for effective treatment solutions within international healthcare systems.

However, the sector encounters substantial hurdles due to the strict regulatory frameworks governing the approval of new treatments. Rigorous compliance requirements and comprehensive safety validations for new drug formulations frequently prolong development schedules and escalate operational expenses. These regulatory obstacles effectively retard the pace at which innovative therapies reach the commercial market, potentially hindering expansion in emerging economies that are still developing their healthcare infrastructure.

Market Driver

The rising global prevalence of thyroid disorders serves as a major driver for market growth, creating a critical need for a reliable supply of hormone replacement therapies. With hypothyroidism rates increasing due to aging demographics and enhanced diagnostic capabilities, reliance on standard treatments such as levothyroxine is intensifying. This consistent patient demand generates substantial commercial volume for established pharmaceutical companies, securing steady revenue within the chronic care sector. For example, Merck Group's November 2025 report indicated that its primary thyroid medication, Euthyrox, achieved 9.6% organic net sales growth driven by robust global demand. Furthermore, an August 2025 press release from the U.S. Food and Drug Administration noted that approximately 22 million patients in the United States were prescribed levothyroxine in 2024, evidencing the heavy disease burden.

Concurrently, the uptake of novel drug formulations is broadening revenue sources beyond traditional generic hormone replacements. Pharmaceutical companies are actively investing in biologics and targeted therapies to manage complex conditions like Thyroid Eye Disease (TED) and refractory thyroid cancers. These innovations provide high-value alternatives to conventional therapies, gaining market share through better clinical results and premium pricing. Amgen Inc., in its third-quarter 2025 financial results, reported that global sales of Tepezza, a targeted treatment for thyroid eye disease, rose by 15% year-over-year to $560 million. This increase in adoption highlights a significant industry shift toward specialized treatments designed to meet specific, unaddressed needs across the thyroid disorder landscape.

Market Challenge

Stringent regulatory frameworks represent a major obstacle to the growth of the Global Thyroid Gland Disorder Treatment Market. Developers are required to navigate intricate compliance protocols and execute comprehensive clinical trials to confirm the safety and efficacy of new treatments. These rigorous demands substantially increase operational expenses and prolong development cycles, resulting in bottlenecks that delay the commercial introduction of innovative drug formulations. As a result, the market struggles to adapt quickly to the changing requirements of healthcare providers and patients, which leads to lost revenue potential and decelerated industry advancement.

The consequences of these regulatory delays are exacerbated by the significant disease burden necessitating prompt and effective care. The American Thyroid Association estimates that in 2025, around 20 million Americans suffer from some type of thyroid condition. This immense patient volume underscores the disparity between the urgent need for advanced therapies and the sluggish pace of product approvals. By hindering the rapid market entry of new treatments, regulatory barriers restrict the industry's capacity to address the needs of this extensive patient population, thereby impeding overall market expansion.

Market Trends

The integration of AI-driven diagnostic and monitoring solutions is revolutionizing the clinical management of thyroid nodules by improving imaging precision and workflow efficiency. Manufacturers are actively incorporating deep learning algorithms into ultrasound systems to aid radiologists in the consistent detection, segmentation, and classification of thyroid lesions. This technological evolution mitigates the subjectivity common in manual examinations, standardizing risk assessment protocols and potentially lowering the rate of unnecessary biopsies for benign nodules. For instance, Samsung Medison's November 2025 press release regarding its new R20 ultrasound system highlights the inclusion of over a dozen AI tools designed to automate measurements and offer real-time diagnostic guidance for complex cases.

Simultaneously, the proliferation of targeted tyrosine kinase inhibitors for thyroid cancer is redefining treatment options for patients with radioactive iodine-refractory disease. As knowledge regarding the molecular causes of thyroid malignancy expands, there is a marked increase in the adoption of precision oncology therapies that block specific pathways like VEGFR and RET. This transition towards molecularly targeted treatments is fueling significant revenue growth for pharmaceutical companies, as these oral medications emerge as standard alternatives to traditional chemotherapy. Exelixis Inc. reported in May 2025 that its flagship tyrosine kinase inhibitor, Cabometyx, achieved net product revenues of $513.3 million for the first quarter, driven by rising demand across oncology indications, including differentiated thyroid cancer.

Key Market Players

• Abbvie Inc.
• Amgen Inc.
• GSK Plc
• Merck KGaA
• Viatris Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Elexis Inc.
• IBSA Group

Report Scope

In this report, the Global Thyroid Gland Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Thyroid Gland Disorder Treatment Market, By Indication

• Hypothyroidism
• Hyperthyroidism

Thyroid Gland Disorder Treatment Market, By Route of Administration

• Oral
• Intravenous
• Others

Thyroid Gland Disorder Treatment Market, By Distribution Channel

• Wholesaler/Distributors
• Retail Chain
• Online Distribution
• Others

Thyroid Gland Disorder Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Thyroid Gland Disorder Treatment Market.

Available Customizations:

Global Thyroid Gland Disorder Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Thyroid Gland Disorder Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Hypothyroidism, Hyperthyroidism)
  • 5.2.2. By Route of Administration (Oral, Intravenous, Others)
  • 5.2.3. By Distribution Channel (Wholesaler/Distributors, Retail Chain, Online Distribution, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Thyroid Gland Disorder Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Thyroid Gland Disorder Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Thyroid Gland Disorder Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Thyroid Gland Disorder Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Thyroid Gland Disorder Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Thyroid Gland Disorder Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Thyroid Gland Disorder Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Thyroid Gland Disorder Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Thyroid Gland Disorder Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Thyroid Gland Disorder Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Thyroid Gland Disorder Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Thyroid Gland Disorder Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Thyroid Gland Disorder Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Thyroid Gland Disorder Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Thyroid Gland Disorder Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Thyroid Gland Disorder Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Thyroid Gland Disorder Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbvie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Amgen Inc.
• 15.3. GSK Plc
• 15.4. Merck KGaA
• 15.5. Viatris Inc.
• 15.6. Novartis AG
• 15.7. Pfizer Inc.
• 15.8. Takeda Pharmaceutical Company Limited
• 15.9. Elexis Inc.
• 15.10. IBSA Group

16. Strategic Recommendations

17. About Us & Disclaimer